Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade
By Dung T Le, Jennifer N. Durham, Kellie N. Smith, Hao Wang, Bjarne R. Bartlett, Laveet K. Aulakh, Steve Lu, H. Kemberling, C. Wilt, Brandon S. Luber and 36 more. Science, 2017
5,893 citations recorded by the source corpus.
Predicting responses to immunotherapy Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have favorable responses to PD-1 blockade immunotherapy. In a phase 2 clinical trial, Le et al. showed that treatment success is not just limited to colon cancer (see the Perspective by Goswami and Sharma). They found that a wide range of different cancer types with MMR deficiency also responded to PD-1 blockade. The trial included some patients with pancreatic cancer, which is one of the deadliest forms of cancer. The clinical trial is still ongoing, and around 20% of patients have so far achieved a complete response. MMR deficiency appears to be a biomarker for predicting successful treatment outcomes for several solid tumors and indicates a new therapeutic option for patients harboring MMR-deficient cancers. Science, this issue p. 409; see also p. 358 A pan-cancer biomarker is identified that can predict successful response to cancer immunotherapy in human patients. The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations. In a proof-of-concept study, we previously showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor–1 (PD-1). We have now expanded this study to evaluate the efficacy of PD-1 blockade in patients with advanced mismatch repair–deficient cancers across 12 different tumor types. Objective radiographic responses were observed in 53% of patients, and complete responses were achieved in 21% of patients. Responses were durable, with median progression-free survival and overall survival still not reached. Functional analysis in a responding patient demonstrated rapid in vivo expansion of neoantigen-specific T cell clones that were reactive to mutant neopeptides found in the tumor. These data support the hypothesis that the large proportion of mutant neoantigens in mismatch repair–deficient cancers make them sensitive to immune checkpoint blockade, regardless of the cancers’ tissue of origin.
Subfields: Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/cefa8bbc701175e2f5a272c2a7a2796d8169477f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pathology and Forensic Medicine
- D. Cua
- S. Gaffen
- M. McGeachy
- L. Diaz
- John N. Weinstein
- Peter W. Laird
- Hans Clevers
- Japanese Gastric Cancer Association
Citations in the corpus
- Deep learning in cancer pathology: a new generation of clinical biomarkers (2020, background): “For example, in treatment-refractory stage IV CRC, MSI is an FDAapproved biomarker for immune-checkpoint-inhibitor-based immunotherapy.(2) In this case, the detection of MSI correlates with the likelihood of a positive therapeutic response, making MSI a strong predictive biomarker in this setting.”
- Cholangiocarcinoma — evolving concepts and therapeutic strategies (2017, neutral): “…in the KEYNOTE028 biliary cancer cohort prompted a successor biliary cancer cohort of 100 patients in the ongoing KEYNOTE158 basket trial (NCT02628067; Patients with MMRdeficient cholangiocarcinoma have also demonstrated responsiveness to treatment with immunecheckpoint inhibitors 166,167,172 .”
- Genomic features of response to combination immunotherapy in patients with advanced non-small cell lung cancer (2018, background): “In patients with advanced cancers treated with PD-1 blockade monotherapy, multiple reports across multiple tumor types (Carbone et al., 2017; Le et al., 2017; Rizvi et al., 2015; Rosenberg et al., 2016; Snyder et al., 2014; Van Allen et al., 2015) have identified an association between increased TMB”
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors (2018, background): “conducted a study to explore the influence of MSI-H on anti-PD-L1 therapy, and satisfactory treatment effect was observed (objective radiographic response rate: 53%, complete response rate: 21%) in multiple cancer patients with dMMR [74].”